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Understanding a process from shallow to deep is necessary for controlling and even curing diseases. The history of
diagnosis and treatment of brainstem gliomas vividly reflects this process. The development of neuroimaging plays a great
role in tumor treatment at different periods, including the period when brainstem gliomas were regarded as an
homogenous incurable disease, and currently it is considered as an entity with high heterogeneity. Presently, it is not
enough to just rely on the conventional neuroimaging techniques to determine the anatomic location of a tumor and its
relationship with normal tissues. The development of molecular genetics and molecular imaging further promotes the
progress of individualized and precision diagnosis and treatment in brainstem gliomas. In this paper, we summarize the
evolution of brainstem glioma radiological classification mainly focusing on the aspects of imaging and surgical treatment.
In the meanwhile, we reviewed the recent progresses in the fields of molecular genetics and molecular imaging.
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The breakthrough of the “no man’s land”
In the 1960s, the brainstem was still the forbidden region
for surgery, and the mortality rate of operation on brain-
stem tumors was nearly 100 %. In 1969, Maston [1] stated
that “regardless of specific histology, brainstem gliomas
must be classified as malignant tumors since their location
itself renders them inoperable.”
Hoffman et al. [2] reported a group of benign brainstem
gliomas with distinct clinical and pathological manifesta-
tions, which originate at the fourth ventricle bottom of the
dorsal part of brainstem, and grow into the fourth ventricle
through the ependyma. Therefore, this kind of tumor was
named as the dorsal exophytic brainstem glioma. Due to
the early age of onset, the common clinical symptoms of
this tumor include elevated intracranial pressure (ICP)* Correspondence: zhangliweittyy@163.com
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article, unless otherwise stated.caused by hydrocephalus and failure to thrive. After total
resection, patients can achieve a relatively long survival
without routine postoperative radiotherapy, and most re-
sidual tumors are stable. The further operation can be con-
sidered when the tumor is relapsed. Although, pathological
studies showed that most patients reported by Hoffman
et al. belong to WHO I–II type fibrillary astrocytoma (only
two cases of patients are ganglioglioma) [2], the most
common pathological type for the dorsal exophytic
brainstem gliomas and diffuse intrinsic pontine gli-
omas (DIPGs) is pilocytic astrocytoma and fibrillary
astrocytoma, respectively [3]. These findings reported
by Hoffman et al. have the epoch-making significance
and subvert the traditional concept that brainstem is
the forbidden region for surgery for many years.Review
From “imagination” to “visualization”
There are four main tasks including localization
diagnosis, qualitative diagnosis, guiding treatment, and
dynamically monitoring of disease evolution following
the treatment, during the development of neuroimagingle is distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
.org/publicdomain/zero/1.0/) applies to the data made available in this
Zhang et al. Chinese Neurosurgical Journal  (2015) 1:4 Page 2 of 6technology. Regarding the treatment of brainstem gliomas,
each technology, such as pneumoencephalography, iodipin
ventriculography, cerebral angiography, CT and MRI, has
made historic contributions for the achieving of these four
tasks. Following the period of “imagination”, it is currently
in the “visualization” period for the diagnosis and treatment
of brainstem gliomas.
The “imagination” refers to a kind of preliminary
diagnosis made by the doctors based on the patient
inquiry and neurological examination before the pres-
ence of neuroimaging techniques. Doctors need to com-
prehensively use their knowledge of physiology and
anatomy to reconstruct and understand the precise loca-
tion and three-dimensional shape of tumor and its rela-
tionship with surrounding normal tissues. Therefore, it
was a great progress from 1917, when a variety of contrast
enhancement techniques have been developed succes-
sively. These imaging techniques can detect the indirect
signs of space occupying lesion in brainstem, improve the
accuracy of diagnosis and provide a relatively objective
basis for surgical exploration together with neurological
examinations. However, these imaging techniques are
invasive methods, which are not able to provide the
patho-histological diagnosis, guide the treatment, and
monitor the effects of treatment, except for providing
the indirect signs of space occupying lesion. After the
clinical use of CT for diagnosis since 1971, the diagnosis
levels were further promoted. CT is a tomography that can
indicate the lesion density and directly show brainstem
tumors. In 1987, Stroink et al. [4] classified the brainstem
tumor into four types based on CT findings of the lesions
and the intraoperative findings, including (I) dorsal exophy-
tic gliomas (iso-density, obvious enhancement), (II) diffuse
intrinsic brainstem tumors (can be divided into IIa, low
density and no enhancement, and IIb, high density and en-
hancement, with exophytic component, (III) focal intrinsic
cystic tumor (cyst wall enhancement), and (IV) focal intrin-
sic solid tumors (iso-density, markable enhancement).
Although this classification can not reflect the whole
imaging manifestations of the brainstem gliomas, it can
predict the expected surgical effect and prognosis to a
certain extent. Moreover, it has the basic parameters
(growth pattern and tumor-imaging features) for imaging
classification in brainstem gliomas. The growth pattern can
be divided into exogenous and endogenous types, and the
latter one can be further divided into diffuse and focal
types. Tumor imaging features on CT can be showed by
the changes of density, with or without enhancement and
cystic degeneration.
Conceptually, this classification reflects a profound
understanding on brainstem gliomas by neurosurgeons
in the 1980s. However, due to the fact of low resolution
of soft tissues, being unable to do three-dimensional
reconstruction, low ability to reflect tumor informationin addition to density and enhancement, as well as bone
artifacts of posterior fossa, CT as an imaging tool did not
make this idea bright. Rapidly, MRI replaced CT and be-
came the main tool for diagnosing and treating brainstem
gliomas due to its several advantages, such as high reso-
lution in soft tissues, three-dimensional reconstruction at
any angle for precise localization, no radioactivity, imaging
sequence diversification, and no bone artifacts.
According to the MRI findings and the observations
during the operation of brainstem gliomas, Epstein
proposed a classification framework in 1985, where
brainstem glioma was classified into exophytic, intrinsic,
and disseminated types [5]. The exophytic type has three
subtypes, including diffuse, focal, and cervicomedullary
subtypes, and the intrinsic type can be divided into sub-
types of cerebellopontine angle (CPA), brachium points,
and fourth ventricle. Epstein [6] reported the surgical
treatment experience of 34 cases of intrinsic brainstem
gliomas in 1986. In this report, all the diffuse tumors
were high-grade gliomas (WHO III–IV), all the cervicome-
dullary tumors were low-grade gliomas (WHO I–II), and
the major focal tumors were low-grade tumors. There were
no surgical benefits in patients with high-grade tumors,
while neurological dysfunction was significantly improved
in patients with cervicomedullary tumors after the oper-
ation, and their diseases were stable for 2 to 5 years post-
operation. Therefore, it is positively suggested to have the
surgical treatment for the patients with cervicomedullary
tumors, but not for the patients with focal tumors which
are highly suspected to be high grade [6, 7].
The classification of Epstein focuses on the growth
pattern based on the hypothesis that different pathological
types of tumors have different growth patterns. Different
growth patterns determine whether the patients should re-
ceive the surgical treatment. Therefore, the cervicomedul-
lary type of brainstem gliomas in this classification does
not only represent the location but also and more import-
antly refer a specific growth pattern. This kind of tumor is
benign, which grows up from the upper cervical spinal
cord, but its growth is limited by the pyramidal decussa-
tion, decussation of lemniscus and pia mater, which change
the growth direction and make the tumor grow into the
fourth ventricle through the ependyma. For these reasons,
the prognosis of this tumor is similar with the intramedul-
lary low-grade tumors, and surgical treatment has good
outcomes [8]. In the classification of Epstein, a dorsal exo-
phytic tumor is one kind of focal benign tumors growing
in the medulla oblongata, and its growth is also limited by
the surrounding fibers, thus changing the growth direction
into the fourth ventricle through the ependyma [8]. The
prognosis of this tumor is good, and the operation can
even cure the disease. The proposal that the growth of
low-grade tumors is limited by the surrounding normal tis-
sues is supported and confirmed by Scherer [9].
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sal exophytic and cervicomedullary type of brainstem
gliomas has been recognized in the late 1980s pro-
moted by Hoffman and Epstein [2, 6, 7]. Both types of
tumors escape from the concept that operation is not
suitable for brainstem gliomas. DIPG is one kind of
brainstem gliomas with the highest incidence, shortest
survival time, and highest difficulty for therapy [10]. Due
to the fact that operation does not exhibit any effect on
this tumor, subsequent studies focused on radiotherapy
and chemotherapy. Since the early 1990s, stereotactic
biopsy, as an invasive tool to acquire histopathological
diagnosis, has been replaced by the noninvasive MRI
examination, because tissue obtained through biopsy
cannot represent the whole of the tumor, thus the
diagnosis may be misleading; besides, knowing the
histopathological diagnosis will not alter the treatment
strategies and prognosis for these patients [11]. However,
the utility of biopsy for DIPGs has been revaluated since
the late 2000s, as those biopsy-based genomic studies of
DIPGs has provided profound knowledge about this
disease [12–14].
It is still unknown whether tumors arisen from differ-
ent segments (such as the medulla oblongata, pons, and
midbrain) of the brainstem but with same pathological
diagnosis share the same rules of tumorigenesis and de-
velopment. In 1990, Barkovich et al. [15] for the first
time introduced the origin of tumor into the classifica-
tion system and proposed novel classification guidelines
based on different parameters, such as growth patterns
(intrinsic/exophytic, diffuse/focal), the locations of tumor
origin (midbrain, pons, medulla oblongata), and character-
istics of the tumor itself (the degree of edema of the brain-
stem, tumor hemorrhage, or necrosis, with or without
hydrocephalus). This classification only provides the
classification foundation, but not reflects the biological
characteristics of tumors from different segments of the
brainstem, because brainstem glioma is a complex disease,
and its imaging findings are various.
In the early 1990s, the role of surgery in midbrain glioma
was well recognized [16–18]. Most midbrain gliomas grow
focally, which can be divided into tectum, tegmental,
and aqueduct gliomas, based on the original locations
[19]. In tectum gliomas, the low- and high-grade tumors
account for 85 and 15 %, respectively [20]. The low-
grade tectum gliomas grow extremely slow, and in the
absence of surgery, patients are able to keep in long-
term stable via V-P shunt or EVT operation [20, 21].
However, the high-grade tectum gliomas grow rapidly
and have very short disease course. A more active ap-
proach is required for the treatment of this kind of
tumor, and the surgery is one of the safe and feasible
treatment strategies [16, 18, 19]. Although the teg-
mental glioma is usually exhibited in low-grade, itsgrowth is significantly faster than that of tectum gli-
oma, and its surgical risk is also greater than tectum
gliomas. There are few reports about the aqueduct gli-
oma, but the current available findings show that most
aqueduct gliomas are low-grade tumors and surgical
resection is safe and feasible for this tumor [19, 22].
Until the early 2000s, brainstem gliomas are gradually
accepted as an highly heterogeneous entity. The surgical
treatment system for brainstem glioma has been basic-
ally established under the guideline of radiological classi-
fication. Many treatment concepts and the results tend
to be consensus, after the surgical resection or sub-
total resection, the dorsal exophytic tumor patients
can get long-term survival and even can be cured.
Most cervicomedullary tumors are low-grade astrocy-
tomas and can gain the good outcome after the oper-
ation. Most midbrain and medulla oblongata focal
tumors are low-grade astrocytomas, and the prognosis
of these tumors can be significantly improved by oper-
ation. However, focal tumors are rare in pons, and
most of them are high-grade gliomas. The operation
for this kind of tumor is safe, but is not able to im-
prove the prognosis [23]. The patients with tectum gli-
omas normally need the treatment with V-P shunt or
third ventriculostomy. The operation is not suitable
for DIPG patients.Unsolved problems by conventional neuroimaging
technology
Until now, imaging technology has exhibited an out-
standing role in precise positioning, demonstrating the
growth pattern, determining the feasibility of operation,
and navigating the precise position in the process of
operation, during the practice of diagnosis and treatment
in brainstem gliomas. However, we are still facing the
problems in the aspects of qualitative diagnosis and the
dynamic monitoring of treatment effect. For example, it
is difficult to use the conventional MRI to distinguish
WHO grade I pilocytic astrocytoma from WHO grade
IV glioblastoma, gliomas from non-gliomas, neoplastic
from non-neoplastic lesions [24–26]. Moreover, it is
unable to detect earlier the response of tumor to
radiotherapy and chemotherapy, for example difficulties
for discriminating pseudo-progress, tumor recurrence,
and radiation-induced necrosis [27]. In addition, it is
unable to do the subdivision on DIPG using the imaging
technology, for example, the radiological manifestations of
child and adult DIPG patients are the same, but their
prognosis and incidence are significantly different
[28–30]. Moreover, the different ages of children also
exhibit the significant differences, for example, the
prognosis of pediatric patients with DIPG younger
than 3–4 years old is better than elder ages [31–33].
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the enormous confusion and challenges in determin-
ing the pathological types of glioma.
The treatment of brainstem glioma promoted by
molecular pathology
The development of molecular pathology first answered
the questions that are not able to be solved by neuroimag-
ing at gene level. The tumor with similar imaging findings
may have totally different molecular genetic events. For
example, the molecular genetic event underlying pilocytic
astrocytoma is the BRAF gene rearrangement [34]. How-
ever, the common genes that mutated in other brainstem
gliomas are TP53, H3F3A, IDH1, PPM1D, and ACVR1
[35–40]. There are significant differences about the mo-
lecular genetics between children and adults DIPGs. The
common mutated genes of children DIPGs are K27M-
H3F3A (70 %) and ACVR1 (20-30 %) [35, 37, 38]. The
prognosis of DIPG patients with K27M-H3F3A mutation
is the worst [35]. ACVR1 mutation coexisted with K27M-
H3.1 mutation, but it excludes each other with K27M-
H3F3A mutation [38]. The DIPG patients with ACVR1
mutation are younger and have longer survival time [37, 38].
The common mutated genes for adult brainstem glioma
are IDH1 and TP53. The mutations of IDH1 and
K27M-H3F3A exclude each other, and they have oppos-
ite effects, and the brainstem glioma patients with
IDH1 mutation have better prognosis [36]. Most brain-
stem gliomas do not have the MGMT promoter
methylation, thus explaining why they are resistant to
temozolomide and other alkylating agents [41, 42],
and the mutations of PPM1D and TP53 would explain
the reason for radiation resistance [36, 43]. The tu-
mors with the same pathological types have distinct
gene mutations between the brainstem and cerebral
hemisphere. K27M-H3F3A mutation is mainly present
in the brainstem and thalamus high-grade gliomas,
while G34V-H3F3A mutation is mainly present in the
cerebral hemisphere gliomas [44]. PPM1D and ACVR1
mutations mainly occur in the brainstem gliomas, but
are rare in supratentorial gliomas [36, 38]. The main
mutation for brainstem pilocytic astrocytoma is the fu-
sion mutation of BRAF-KIAA1549 [34], and that for
sellar area pilocytic astrocytoma is the mutation of
V600E BRAF [45]. All these molecular genetic findings
confirm the essential difference between brainstem gli-
omas and supratentorial gliomas, which explain why
chemotherapy is effective for supratentorial gliomas,
but not for brainstem gliomas [42, 10].
In addition to elucidating the molecular mechanisms
underlying the heterogeneity of brainstem gliomas, the
development of the molecular pathology provides the
potential therapeutic targets (such as ACVR1, PPM1D,
IDH1, H3F3A, and BRAF) for drug development in thefuture. We believe that with the advancement of mo-
lecular pathology on the brainstem gliomas, a compre-
hensive pathological classification will greatly improve
the prognosis of brainstem gliomas.
The advancement of neuroimaging and molecular
imaging
In the recent 10 years, the molecular pathology has
gradually replaced the histopathology as the gold stand-
ard for guiding the personal diagnosis and treatment of
gliomas. However, the diagnosis by molecular pathology
only reflects the information of selected location, but
not the whole tumor, and this method is limited for
repeated sample collection, thus inducing the difficulties
of molecular pathology in dynamic monitoring changes
during the tumor treatment. In contrast, tumor imaging
can reflect the whole information of tumor and also
dynamically monitor the changes during the treatment
process. It is necessary to combine these two disciplines
if we want to take their advantages. Imaging genomics,
imaging proteomics, and imaging metabolomics represent
the new branch in science that link currently used imaging
modalities to predict and correlate genomic, proteomic,
and metabolic profiles in gliomas [46–49]. Among them,
the fastest growing discipline is the imaging genomics in
the filed of glioblastoma multiforme (GBM).
Raza et al. investigated the relationship between the
degree of necrosis of GBM and gene expression profiles
in 2004 and found that 26 genes are associated with
GBM necrosis [46]. Diehn et al. [50] found that overex-
pression of EGFR is associated with the higher
contrast-to-necrosis ratio. Pope et al. [51] confirmed
that the expression of IL-8 and VEGF in completely
enhancement GBM patients is significantly higher than
that in incompletely enhancement patients. In 2011,
Zinn et al. [52] identified the peritumoral MRI-FLAIR
phenotype as an imaging surrogate for GBMs highly
enriched in genes and miRNAs involved in cellular mi-
gration/invasion and specifically identified a gene and
miRNA functional axis involved in invasion. These find-
ings for the first time confirm that POSTN gene and its
regulator miRNA-219 are associated with a highly signifi-
cant decrease in survival, imaging characteristics of inva-
sion, and a specific subclass of GBM, the mesenchymal
subclass. Magnetic resonance perfusion (MRP) imaging is
associated with the expression levels of pro-angiogenic
genes [53]. However, these studies are still at statistical
level, and their conclusions are not applied for the individ-
ual decision during the process of clinical practice. In
addition, magnetic resonance spectroscopy (MRS) can de-
tect carcinogenic product 2-hydroxyglutarate induced by
the intratumoral IDH1/2 gene mutation [54]. This is the
technology that is currently able to assist personal therapy
and observe the treatment efficacy.
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the metabolism, the positron emission tomography
(PET)/CT has been utilized in the diagnosis and therapy
guidance of brainstem gliomas and yielded its benefits
comparing to the traditional imaging techniques. Pirotte
et al. integrated PET/CT images into the planning for
stereotactic biopsy procedures to direct the biopsy needle's
trajectory to hypermetabolic foci of intrinsic infiltrative
brainstem lesions in 20 children, and found that 18 F-FDG
and 11C-Methionine (MET) PET could help point out
more accurate diagnostic yield for biopsy to get the tumor
tissue for pathology determination than MRI alone. PET
guidance could improve the sampling and reduce the
numbers of sampling procedures. It was this study that
strengthened the role of stereotactically guided biopsy
procedures which was once questioned in intrinsic
infiltrative brainstem lesions [55]. The tumor metabolism
molecular imaging could yield some prognostic marker
for brainstem gliomas. A report of Pediatric Brain Tumor
Consortium from a research of 40 children of newly
diagnosed diffuse intrinsic brainstem gliomas found that
the patients with 18 F-FDG uptake involves at least half
the tumor had the poorer survival than those with uptake
in less than 50 % of the tumor [56]. In the future, PET/
MRI, which combines the advantage of high sensitivity of
PET and high resolution of MRI, will be used more widely
than before [47]. What is more, with the identification of
tumor-specific proteins and genes, more and more im-
aging tracers, including antibody, peptides, and small mo-
lecular chemicals, will be designed for a great breakthrough
in cancer diagnosis, differential diagnosis, and dynamic
monitoring.
A great progress in the genomics of brainstem glioma has
been made in the recent 5 years, such as the BRAF, H3F3A,
ACVR1, PPM1D, and IDH1 genes have been successively
identified [34–40]. The imaging genomics of brainstem gli-
oma is still completely unknown. We believe that rapid de-
velopment in this field will be gained in the future.
Conclusion
Brainstem glioma is a group of highly heterogeneous dis-
ease, and the cooperation among multiple disciplines is ne-
cessary to cure this disease. Improving the molecular
pathological classification of brainstem glioma is the basis
of the personal diagnosis and therapy. It is necessary to
combine the imaging with molecular pathology, thus de-
veloping novel method that is noninvasive, comprehensive,
and able to dynamically monitor the treatment of cancer.
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